March 1 (Bloomberg) -- LadaTech LLC, a biotech company partly owned by GlaxoSmithKline Plc, won a jury verdict that rival Illumina Inc. infringed a patent for gene-manipulation techniques used in diagnosing disease.
The jury in federal court in Wilmington, Delaware, also decided that the patent owned by LadaTech, of Larchmont, New York, is valid and enforceable, according to court papers.
LadaTech sued San Diego-based Illumina in 2009. The trial was supervised by U.S. District Judge Sue Robinson. The jury didn’t rule on damages. That phase of the case hasn’t been scheduled.
“This verdict is an important reaffirmation of the importance of the LadaTech patent” Chief Executive Officer Nicholas Didier said in a statement today.
Illumina intends to appeal the jury’s finding of infringement, the company said in a statement.
“We believe that we acted properly with respect to the LadaTech patent and that, ultimately, our position will be vindicated,” Jay Flatley, Illumina’s chief executive, said in a statement.
The case is LadaTech LLC v. Illumina Inc., 09CV627, U.S. District Court, District of Delaware (Wilmington).
To see the patent, click: 6,107,023.